A phase 3 trial examining toripalimab, combined with chemotherapy and radiotherapy without concurrent cisplatin, showed comparable efficacy and reduced toxicity in locoregionally advanced nasopharyngeal carcinoma patients. With a median follow-up of 37 months, the 3-year failure-free survival was 88.3% in the cisplatin-sparing group versus 87.6% in the standard group. Adverse events such as vomiting and anemia were less frequent without cisplatin. The study involved 532 patients from 13 hospitals in China and highlighted optimism for future research with ongoing trials on PD-1 blockade regimens.

Source: JAMA